CT Lymphnodal Staging of Gastric Cancer by New TNM Staging System: Reassessment of the Size Criteria of Lymph Nodes

Jung, Hyun Suk; Lee, J M; Sohn, Kyung-Myung; Lee, S Y; Park, S M; Kim, K M

doi:10.3348/jkrs.2000.42.1.101

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…상기 수술 전 선행 항암화학요법의 장단점 중, 우수한 내약성, 생 체 내 약제 감수성 확인, 종양 크기 및 병기의 감소는 위암에도 적용 될 수 있음이 기존 보고에서 확인되고 있다. Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) 연구에서는 503명의 환자를 대상으로 수술 단독 군과 수술 전후 epirubicin, cisplatin, 5-fluorouracil (5-FU) (ECF) 3제 병용 항암화학요법의 효과를 비교하였다 [7] [16]. 다중검출 전산화단층촬영(multidetector-row computed tomography)을 시행할 경우 T 병기의 정확도는 77%-89%, N 병기의 정확도는 59%-78%로 보고되고 있다 [17][18][19].…”

unclassified

Neoadjuvant chemotherapy in localized resectable stomach cancer

Ryu¹

2014

Korean J Clin Oncol

View full text Add to dashboard Cite

In localized resectable stage II or III gastric cancer, D2 dissection has been accepted as the standard surgical method worldwide. The Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer and Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer phase III trials have demonstrated that systemic adjuvant chemotherapy can significantly improve recurrence-free survival (RFS) and overall survival (OS) after D2 dissection with absolute survival benefit of 10% to 15% compared with surgery alone. Addition of radiation or intensification of adjuvant chemotherapy has been tried in localized resectable gastric cancer for further improvements of RFS and OS as well. However, addition of radiation after D2 dissection was proven to play no or only a minimal role at its best in reduction of loco-regional recurrences as well as distant metastases. The results of recent large-scale adjuvant trials suggest that more intensified adjuvant treatment including multiple chemotherapeutic agents would not likely induce a better result. For this reason, addition of neoadjuvant chemotherapy to current standard of care may be the only plausible strategy to improve long-term outcomes in localized resectable gastric cancer, and clinical trials of neoadjuvant chemotherapy are now ongoing in gastric cancer.

show abstract

unclassified

Neoadjuvant chemotherapy in localized resectable stomach cancer

Ryu¹

2014

Korean J Clin Oncol

View full text Add to dashboard Cite

show abstract

CT Lymphnodal Staging of Gastric Cancer by New TNM Staging System: Reassessment of the Size Criteria of Lymph Nodes

Cited by 1 publication

References 2 publications

Neoadjuvant chemotherapy in localized resectable stomach cancer

Neoadjuvant chemotherapy in localized resectable stomach cancer

Contact Info

Product

Resources

About